Combined sodium glucose co‐transporter‐2 inhibitor and angiotensin‐converting enzyme inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial-Reference-Cited by-同舟云学术

Combined sodium glucose co‐transporter‐2 inhibitor and angiotensin‐converting enzyme inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial

Published:2022-01-24 Issue:5 Volume:24 Page:816-826
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Antlanger Marlies¹²,Domenig Oliver³,Kaltenecker Christopher C.²,Kovarik Johannes J.²,Rathkolb Vincent²,Müller Martin M.²,Schwaiger Elisabeth¹²,Hecking Manfred²,Poglitsch Marko³,Säemann Marcus D.⁴⁵,Kopecky Chantal²⁶^ORCID

Affiliation:

1. Department of Internal Medicine II Kepler University Hospital Linz Austria

2. Department of Internal Medicine III, Division of Nephrology and Dialysis Medical University of Vienna Vienna Austria

3. Attoquant Diagnostics GmbH Vienna Austria

4. 6th Medical Department with Nephrology and Dialysis Wilhelminenhospital Clinic Ottakring Vienna Austria

5. Medical Faculty Sigmund Freud University Vienna Austria

6. Faculty of Medicine, School of Medical Sciences University of New South Wales Sydney Australia

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject